2.00Open2.00Pre Close0 Volume55 Open Interest2.50Strike Price0.00Turnover967.88%IV23.29%PremiumAug 16, 2024Expiry Date1.15Intrinsic Value100Multiplier13DDays to Expiry0.85Extrinsic Value100Contract SizeAmericanOptions Type0.8746Delta0.0298Gamma1.39Leverage Ratio-0.0528Theta0.0002Rho1.22Eff Leverage0.0015Vega
Shattuck Labs Stock Discussion
Benzinga
The company observed 67% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete remission (CR)/marrow complete remission (mCR) rate of 58% and median overall survival had no...
Shattuck Labs Granted Orphan Drug Designation By FDA For SL-172154 In Acute Myeloid Leukemia
NEWS
Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
Shattuck Labs, Inc. reveals preclinical data at AACR Annual Meeting 2024 showing TRIM7 inhibition can combat immune checkpoint therapy resistance. TRIM7 inhibitors may reverse acquired resistance to PD-1/L1 blockade, potentially benefiting cancer patients.
No comment yet